美通社

2024-09-26 20:28

ArkBio Announces Publication of Phase 3 Clinical Trial Results of Ziresovir for the Treatment of RSV Infection in The New England Journal of Medicine

SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a clinical stage biopharmaceutical company focused on the development of therapeutics in respiratory, infectious and pediatric diseases, announced that the results of the phase 3 clinical trial of ziresovir, an oral drug for treatment of respiratory syncytial virus (RSV) infection in infants and young children, have been published as an original article entitled "Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus"in The New England Journal of Medicine (NEJM). This marks the first time that NEJM has published phase 3 clinical trial results of a direct-acting antiviral drug treating RSV infection. This landmark study, led by Professors Xin Ni and Shunying Zhao from Beijing Childrens'Hospital, Capital Medical University, represents a significant milestone in the field of RSV antiviral development, where worldwide, there are no effective treatments for RSV infections available. In addition, the NEJM publication is accompanied by an editorial written by Professor Edward Walsh entitled "Creeping Towards Effective Antiviral Agents for RSV Infection", which regards the results of the phase 3 ziresovir clinical study to be encouraging.

RSV is the leading cause of hospitalized infants with respiratory infections and can cause serious respiratory complications such as bronchiolitis and pneumonia. For high-risk premature infants and those with congenital conditions, RSV infection can be serious and potentially life-threatening. Moreover, infants who suffer from an RSV infection are at a significantly higher risk of recurrent wheezing and asthma in later childhood. Among adults, severely immunocompromised patients and the elderly are at the highest risk for severe RSV infection, which can lead to hospitalization and death.

A total of 30 leading children's hospitals or pediatric departments of general hospitals across China participated in this randomized, double-blind, placebo-controlled phase 3 clinical trial, enrolling 311 infants or young children aged 1 to 24 months who were hospitalized due to RSV infection. These participants were randomly assigned in a 2:1 ratio to ziresovir or placebo twice a day for a 5-day treatment period. The primary outcome measure was the change in the Wang bronchiolitis clinical score from baseline after 48 hours of treatment. The key secondary endpoint was the change in RSV viral load from baseline after 96 hours of treatment.

Study Results:

  • Significant Efficacy: In the ziresovir treatment group, the average reduction in bronchiolitis clinical score was 3.4 points after 48 hours of the first dose, compared to a 2.7-point reduction in the placebo group which reached statistical significance (P=0.002).
  • Significant Reduction in Viral Load: The ziresovir treatment group showed an average decrease in RSV viral load of 2.5 log10 copies/mL 96 hours after the first dose, while the placebo group showed a decrease of 1.9 log10 copies/mL, representing a 77% greater reduction in the treatment group which was statistically significant (P=0.006).
  • Excellent Safety Profile: The incidence of drug-related adverse events was 16% in the ziresovir treatment group and 13% in the placebo group. No serious drug-related adverse events were observed and there were no deaths.

These results indicate that as a novel direct-acting oral antiviral drug, ziresovir is an effective treatment for infants and young children hospitalized with RSV infection and has a favorable safety profile.

Professor Xin Ni, a leading principal investigator of Beijing Children's Hospital, Capital Medical University, stated: "RSV infection has long been a serious medical challenge in pediatric healthcare. This virus not only poses a threat to children's health, but also places a heavy burden on our healthcare system. For a long time, we have been searching for a safe and effective treatment. Today, our team has made significant progress in the management of this illness. We are grateful to The New England Journal of Medicine for recognition of our clinical study. This is the first successful phase 3 clinical trial of a direct-acting antiviral drug for the treatment of hospitalized infants with RSV infection. This research will bring hope to millions of families with their children being infected by RSV globally. We look forward to the approval of ziresovir for treatment of RSV infection in China and around the world for children to grow up free from the threat of RSV infection".

Dr. Jim Wu, CEO of ArkBio, added:"The phase 3 clinical trial results of ziresovir in the treatment of hospitalized infants and young children are encouraging, as the study confirms that ziresovir is a well-tolerated and efficacious antiviral drug for the treatment of RSV infection. As the sponsor of the study, we are deeply grateful to all the patients and parents, the investigators and their teams, and all our partners who actively participated in the study. Under the guidance of the regulatory agencies, we will continue to develop the drug in collaboration with the medical community. We are committed to the research and development of innovative medicines to safeguard the wellbeing and healthy growth of children".

About ziresovir

Ziresovir is a novel small-molecule RSV fusion (F) protein inhibitor. It binds to the F protein of the virus and prevents viral entry into human cells. Ziresovir can also suppress RSV viral transmission by blocking cell-to-cell fusion through the formation of "syncytia", a characteristic event of RSV infection of host cells.
Ziresovir is the first oral anti-RSV drug that has completed a phase 3 pivotal clinical study with positive results. Ziresovir is the first non-oncology investigational product that received Breakthrough Therapy designation by the National Medical Products Administration (NMPA) of China.

About ArkBio

ArkBio is a global biotech company focusing on discovery and development of innovative drugs for unmet medical needs, especially in the therapeutic areas of respiratory, infectious and pediatric diseases. Since its inception in 2014, the company has established core technology platforms and built an innovative and highly differentiated R&D pipeline through in-house R&D efforts and external collaborations. This strong R&D pipeline program includes innovative clinical and pre-clinical stage drug candidates with first- or best-in-class potential for global clinical development. As one of the core assets, ziresovir is the first direct-acting RSV antiviral drug that has been developed by ArkBio.

ArkBio has established strategic partnerships with several global pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture investment institutions. 

For more information about the company, please visit our website: www.arkbiosciences.com

Investor Inquiries: IR@arkbiosciences.com

source: Arkbio

【你點睇?】美國總統特朗普批評烏克蘭總統澤連斯基是「一位未經選舉的獨裁者」,俄烏戰爭早應停止。你是否認同特朗普的說法?► 立即投票

上一篇新聞︰2024-09-26 20:53  香港數碼娛樂協會 於「2024東京電玩展」設「香港館」

下一篇新聞︰2024-09-26 20:28  「秋季家居博覽2024」正式開幕

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
4
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
5
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
6
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
9
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
10
一本萬利 | 2025年的五個「勿」(有片)
11
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
12
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
13
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
14
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
15
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
16
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
17
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
18
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
19
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
20
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
21
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
22
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
23
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
24
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
25
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
26
高息定存 | 信銀國際12個月港元定存高達3.5厘
27
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
28
David Webb:因病情惡化,將有序結束個人財經網站
29
民營企業座談會 | 習近平在京出席民營企業座談會
30
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

2025-26年度財政預算案

大國博弈

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老